TheraRadar
← Back
Data updated: May 24, 2026

REDDYS

Generics

REDDYS is a generic drug manufacturer focused on Neurology, Dermatology, Immunology.

2010
Since
3
Drugs
-
Trials
0
New Drugs (2yr)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

No active drugs

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Neurology 39%
1 drugs Phase 3: 2 Phase 2: 2 Phase 1: 1
Dermatology 24%
0 drugs Phase 3: 2 Phase 2: 2
Immunology 20%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 2
Oncology 10%
0 drugs Phase 3: 1 Phase 1: 1
Infectious Disease 6%
0 drugs Phase 2: 1 Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

6
Phase 3
7
Phase 2
5
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling